Inhibikase Therapeutics (IKT) Other Non-Current Assets (2025 - 2026)

Inhibikase Therapeutics' (IKT) quarterly Other Non-Current Assets came in at $155759.0 in Q1 2026, up 63.75% on a QoQ basis from $95121.0 in Q4 2025.

Inhibikase Therapeutics (IKT) Other Non-Current Assets (2025 - 2026) Analysis & Trends

Inhibikase Therapeutics (IKT) has 2 years of Other Non-Current Assets data on file, last reported at $155759.0 in Q1 2026.

On a quarterly basis, Other Non-Current Assets changed N/A year-over-year to $155759.0 in Q1 2026; TTM through Mar 2026 was $155759.0, a N/A change from a year earlier, with the FY2025 full-year figure at $95121.0, changed N/A from the prior year.
Other Non-Current Assets for Q1 2026 stood at $155759.0, up from $95121.0 in the prior quarter.
Over the last five years, Other Non-Current Assets for IKT reached as high as $155759.0 in Q1 2026 and fell as low as $57913.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Other Non-Current Assets (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	1.02 Mn
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	60,000.00
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	104.24 Mn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	1.26 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	2.13 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-	289.41 Mn
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	14.48 Mn
10	Inhibikase Therapeutics	407.51 Mn	237.14 Mn	-	155,759.00

Download Data